Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
NEW YORK (Reuters Health) – Despite its known cardiotoxic effect, trastuzumab is associated with a relatively low risk of congestive heart failure in women being treated for HER2-positive…
NEW YORK (Reuters Health) – A retrospective multicenter study conducted in France concludes that combination chemotherapy with gemcitabine and oxaliplatin is effective in patients with advanced hepatocellular carcinoma…
NEW YORK (Reuters Health) – Compared to open radical prostatectomy in patients with recurrent prostate cancer after failed primary therapy, robotic-assisted laparoscopic prostatectomy “is an attractive alternative”, and…
NEW YORK (Reuters Health) – Whole-body (WB) scans using either magnetic resonance imaging (MRI) or positron-emission tomography (PET) with CT, both have high sensitivity and specificity in detecting…
NEW YORK (Reuters Health) – The theoretical advantage of a retrograde rather than antegrade approach to nerve sparing during robot-assisted radical prostatectomy (RARP) has been confirmed in a…
NEW YORK (Reuters Health) – After platinum failure in patients with advanced non-small-cell lung cancer, adding aflibercept to standard second-line docetaxel treatment does not improve overall survival (OS),…
NEW YORK (Reuters Health) – Using a hybrid of single-photon emission computed tomography (SPECT) and computed tomography (CT) to look for positive lymph nodes in melanoma patients helps…
NEW YORK (Reuters Health) – In the first-line treatment of advanced colorectal cancer, the combination of cediranib and chemotherapy is comparable to bevacizumab plus chemotherapy in terms of…
NEW YORK (Reuters Health) – Chemotherapy-induced delayed nausea remains a significant problem, despite the availability of second-generation antiemetics, researchers say. In a study they conducted, over half of…
NEW YORK (Reuters Health) – In advanced ovarian cancer, extensive lymph node dissection in a second-look operation does not improve survival, Italian researchers say. Their randomized trial addressed…
